S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:SLGC

Standard BioTools (SLGC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$1.93
$2.31
50-Day Range
$2.10
$2.83
52-Week Range
$1.73
$3.79
Volume
33.91 million shs
Average Volume
10.83 million shs
Market Capitalization
$394.95 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.26
SLGC stock logo

About Standard BioTools Stock (NASDAQ:SLGC)

SomaLogic, Inc. operates as a protein biomarker discovery and clinical diagnostics company in the United States. It develops slow off-rate modified aptamers (SOMAmers), which are modified nucleic acid-based protein binding reagents that are specific for its cognate protein; and offers proprietary SomaScan services, which provide multiplex protein detection and quantification of protein levels in complex biological samples. The company's SOMAmers/SomaScan technology enables researchers to analyze various biological samples for protein biomarker signatures, which are utilized in drug discovery and development. Its SomaScan's biomarker discoveries use in diagnostic applications for various diseases, including cardiovascular and metabolic disease, nonalcoholic steatohepatitis, wellness, and others. The company also provides SomaSignal, a laboratory-developed test. It serves pharmaceutical and biotechnology companies, and academic and government research institutions. The company has a collaboration agreement with Illumina Cambridge, Ltd for the development of co-branded NGS-based proteomic distributable kits. The company was founded in 1999 and is headquartered in Boulder, Colorado.

SLGC Stock News Headlines

LAB May 2024 2.500 call
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
“The Stock Market’s Bull Run is Far from Over” -Barrons
Barron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!
SomaLogic Inc Class A
See More Headlines
Receive SLGC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Standard BioTools and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Current Symbol
NASDAQ:SLGC
Fax
N/A
Employees
451
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.26
High Stock Price Target
$7.00
Low Stock Price Target
$2.30
Potential Upside/Downside
+102.9%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-109,160,000.00
Net Margins
-159.54%
Pretax Margin
-159.08%

Debt

Sales & Book Value

Annual Sales
$97.67 million
Book Value
$3.00 per share

Miscellaneous

Free Float
160,049,000
Market Cap
$394.95 million
Optionable
Optionable
Beta
1.64
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Dr. Stephen A. Williams BS (Age 64)
    MB, Ph.D., Chief Medical Officer
    Comp: $648.03k
  • Mr. Adam Taich (Age 49)
    Interim CEO
  • Mr. Pi Zheng (Age 51)
    Interim Chief Accounting Officer
  • Dr. Jason Cleveland Ph.D.
    Chief Technology Officer
  • Dr. Nebojsa Janjic Ph.D. (Age 63)
    Chief Science Officer
  • Mr. Ruben Gutierrez J.D. (Age 49)
    General Counsel
  • Ms. Alison Marie Roelke (Age 49)
    Chief People Officer
  • Dr. Shane Bowen Ph.D.
    Chief Research & Development Officer

SLGC Stock Analysis - Frequently Asked Questions

Should I buy or sell Standard BioTools stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Standard BioTools in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SLGC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SLGC, but not buy additional shares or sell existing shares.
View SLGC analyst ratings
or view top-rated stocks.

What is Standard BioTools' stock price target for 2024?

3 analysts have issued 12-month price targets for Standard BioTools' stock. Their SLGC share price targets range from $2.30 to $2.50. On average, they predict the company's stock price to reach $2.43 in the next year. This suggests a possible upside of 15.9% from the stock's current price.
View analysts price targets for SLGC
or view top-rated stocks among Wall Street analysts.

What ETF holds Standard BioTools' stock?

ARK Genomic Revolution ETF holds 13,104,112 shares of SLGC stock, representing 1.22% of its portfolio.

Who are Standard BioTools' major shareholders?

Standard BioTools' stock is owned by many different retail and institutional investors. Top institutional investors include SG Americas Securities LLC (0.05%), Citadel Advisors LLC (0.00%) and HAP Trading LLC (0.00%). Insiders that own company stock include Adam Taich, Alison Marie Roelke and Ruben Gutierrez.
View institutional ownership trends
.

This page (NASDAQ:SLGC) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners